Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)-Reference-Cited by-同舟云学术

Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)

Published:2017-01-19 Issue:11 Volume:123 Page:1958-1964
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kim Youjin¹,Lee Su Jin¹,Lee Ji Yun¹,Lee Se-Hoon¹,Sun Jong-Mu¹,Park Keunchil¹,An Ho Jung²,Cho Jae Yong³,Kang Eun Joo⁴,Lee Ha-Young⁵,Kim Jinsoo⁶,Keam Bhumsuk⁷,Kim Hye Ryun⁸,Lee Kyoung Eun⁹,Choi Moon Young¹⁰,Lee Ki Hyeong¹¹,Ahn Myung-Ju¹

Affiliation:

1. Division of Hematology-Oncology; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul Korea

2. St Vincent's Hospital; Catholic University; Suwon South Korea

3. Gangnam Severance Hospital; Yonsei University College of Medicine; Seoul Korea

4. Guro Hospital; Korea University Medical Center; Seoul Korea

5. Dongnam Institute of Radiological and Medical Sciences; Busan Korea

6. Boramae Medical Center; Seoul National University Hospital; Seoul Korea

7. Seoul National University Hospital; Seoul Korea

8. Yonsei Cancer Center; Yonsei University College of Medicine; Seoul Korea

9. Ewha Womans University Medical Center; Seoul Korea

10. Paik Hospital; Inje University; Gimhae Korea

11. Chungbuk National University Hospital; Cheongju Korea